Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Solange Peters, Richard Cathomas et al.|The Lancet|2015Cited by 392
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|European Journal of Cancer|2017Cited by 27
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00).Miklos Pless, Roger Stupp, Hans‐Beat Ris et al.|Journal of Clinical Oncology|2013Cited by 19
Final Results of the Sakk 16/00 Trial: a Randomized Phase III Trial Comparing Neoadjuvant Chemoradiation to Chemotherapy Alone in Stage Iiia/N2 Non-Small Cell Lung Cancer (Nsclc)Miklos Pless, Sönke Peters, Roger Stupp et al.|Annals of Oncology|2014Cited by 13
Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients (pts) with locally advanced, k-ras-mutated rectal cancer (LARC): A phase I/II trial SAKK 41/08.Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|Journal of Clinical Oncology|2014Cited by 5